Phaseline

Companies › Insmed Gene Therapy

Insmed Gene Therapy: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Neurology; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
INS1201
Gene therapy for Duchenne muscular dystrophy
DMDPhase 1Duchenne Muscular DystrophyJan 2028
INS1202
Gene therapy targeting SOD1 mutations
SOD1Phase 1Amyotrophic Lateral SclerosisMar 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06817382INS1201Phase 1Duchenne Muscular DystrophyNeurologyJan 2028
NCT07290062INS1202Phase 1Amyotrophic Lateral SclerosisNeurologyMar 2030

Targets

SOD1 (1) DMD (1)

Companies with the same targets

Solid Biosciences NS Pharma Sarepta Therapeutics UniQure Biopharma Biogen Regeneron Pharmaceuticals Dyne Therapeutics Avidity Biosciences REGENXBIO Precision BioSciences

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.